The HARMONi trial, a Phase 3 randomized study, was the first trial to demonstrate a notable clinical benefit of Ivonescimab plus chemotherapy in patients with EGFR-TKI-resistant NSCLC [25]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.